MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
MangoRx (NASDAQ: MGRX), a company focused on men's health and wellness products, has responded to claims made by Eli Lilly. Eli Lilly has allegedly filed a lawsuit against MangoRx, claiming that the company improperly copied its weight-loss medicines, Zepbound and Mounjaro. MangoRx strongly refutes these claims regarding the sale of compounded tirzepatide and intends to vigorously defend itself.
The company believes it has strong arguments against Eli Lilly's claims and remains committed to providing access to safe and efficacious products prescribed by U.S. licensed practitioners. MangoRx plans to continue enhancing patient care through innovative solutions while striving to comply with regulatory guidelines.
MangoRx (NASDAQ: MGRX), un'azienda focalizzata su prodotti per la salute e il benessere maschile, ha riscontrato le affermazioni fatte da Eli Lilly. Eli Lilly ha presumibilmente intentato una causa contro MangoRx, sostenendo che l'azienda abbia copiato in modo improprio i suoi farmaci per la perdita di peso, Zepbound e Mounjaro. MangoRx rigetta fermamente queste affermazioni riguardo alla vendita di tirzepatide composto e intende difendersi vigorosamente.
L'azienda crede di avere argomentazioni forti contro le affermazioni di Eli Lilly e rimane impegnata a fornire accesso a prodotti sicuri ed efficaci prescritti da professionisti autorizzati negli Stati Uniti. MangoRx prevede di continuare a migliorare la cura del paziente attraverso soluzioni innovative, mantenendo al contempo la conformità alle linee guida normative.
MangoRx (NASDAQ: MGRX), una empresa enfocada en productos de salud y bienestar masculino, ha respondido a las afirmaciones hechas por Eli Lilly. Eli Lilly supuestamente ha presentado una demanda contra MangoRx, alegando que la empresa copió indebidamente sus medicamentos para la pérdida de peso, Zepbound y Mounjaro. MangoRx refuta enérgicamente estas afirmaciones con respecto a la venta de tirzepatida compuesta y tiene la intención de defenderse vigorosamente.
La empresa cree que tiene argumentos sólidos contra las afirmaciones de Eli Lilly y sigue comprometida a proporcionar acceso a productos seguros y eficaces prescritos por profesionales autorizados en EE. UU. MangoRx planea continuar mejorando la atención del paciente a través de soluciones innovadoras mientras se esfuerza por cumplir con las pautas regulatorias.
MangoRx (NASDAQ: MGRX)는 남성 건강 및 웰빙 제품에 중점을 둔 회사로, Eli Lilly의 주장에回应했습니다. Eli Lilly는 MangoRx를 상대로 소송을 제기했다고 주장하며, 이 회사가 체중 감소 약물인 Zepbound와 Mounjaro를 부정하게 복사했다고 주장하고 있습니다. MangoRx는 복합 tirzepatide의 판매에 관한 이러한 주장을 강력히 반박합니다 및 적극적으로 변호할 것입니다.
회사는 Eli Lilly의 주장에 대해 강력한 논거가 있다고 믿으며, 미국 면허가 있는 전문의가 처방하는 안전하고 효과적인 제품에 대한 접근을 제공하는 데 전념하고 있습니다. MangoRx는 규제 지침을 준수하면서 혁신적인 솔루션을 통해 환자 치료 개선을 계속할 계획입니다.
MangoRx (NASDAQ: MGRX), une entreprise axée sur les produits de santé et de bien-être pour les hommes, a répondu aux allégations formulées par Eli Lilly. Eli Lilly aurait intenté un procès contre MangoRx, affirmant que l'entreprise avait copié de manière inappropriée ses médicaments pour la perte de poids, Zepbound et Mounjaro. MangoRx conteste fermement ces allégations concernant la vente de tirzépatid composé et entend se défendre vigoureusement.
L'entreprise estime avoir de solides arguments contre les allégations d'Eli Lilly et reste engagée à fournir un accès à des produits sûrs et efficaces prescrits par des praticiens autorisés aux États-Unis. MangoRx prévoit de continuer à améliorer les soins aux patients grâce à des solutions innovantes tout en s'efforçant de respecter les directives réglementaires.
MangoRx (NASDAQ: MGRX), ein Unternehmen, das sich auf Produkte für die Männergesundheit und -wohlbefinden konzentriert, hat auf die Behauptungen von Eli Lilly reagiert. Eli Lilly hat angeblich eine Klage gegen MangoRx eingereicht und behauptet, das Unternehmen habe unrechtmäßig seine Gewichtsreduktionsmedikamente Zepbound und Mounjaro kopiert. MangoRx widerspricht diesen Behauptungen entschieden bezüglich des Verkaufs von kombiniertem Tirzepatid und beabsichtigt, sich energisch zu verteidigen.
Das Unternehmen ist überzeugt, dass es starke Argumente gegen die Ansprüche von Eli Lilly hat, und bleibt verpflichtet, den Zugang zu sicheren und wirksamen Produkten zu gewährleisten, die von lizenzierten Praktikern in den USA verschrieben werden. MangoRx plant, die Patientenversorgung weiterhin zu verbessern durch innovative Lösungen und gleichzeitig die Einhaltung der regulatorischen Richtlinien zu verfolgen.
- MangoRx believes it has strong arguments against Eli Lilly's claims
- The company remains committed to providing safe and efficacious products
- MangoRx plans to continue offering innovative solutions for patient care
- Eli Lilly has filed a lawsuit against MangoRx for allegedly copying its weight-loss medicines
- The lawsuit could potentially impact MangoRx's business operations and reputation
Insights
This lawsuit by Eli Lilly against MangoRx over alleged improper copying of weight-loss medications Zepbound and Mounjaro is a significant development in the pharmaceutical industry. The core issue revolves around intellectual property rights and the legality of compounded versions of branded drugs.
MangoRx's strong refutation and intention to "vigorously defend" suggests they believe their practices are lawful, possibly relying on compounding pharmacy regulations. However, Eli Lilly, as a major pharmaceutical company, likely has substantial resources to pursue this case.
The outcome could have far-reaching implications for the compounding pharmacy industry and access to lower-cost alternatives of branded medications. If Eli Lilly prevails, it may deter other companies from offering compounded versions of patented drugs, potentially affecting drug pricing and availability.
Investors should monitor this case closely, as it could impact MangoRx's business model and future revenue streams. The legal battle may also incur significant costs for MangoRx, which could strain its finances given its relatively small market cap of
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly’s claims and intends to vigorously defend itself in this matter.
MangoRx’s focus is, and will continue to be, providing access to safe and efficacious products to serve patients who have been deemed medically appropriate to consume its products by U.S. licensed practitioners. MangoRx remains committed to its mission and plans to continue to enhance patient care by offering new and innovative solutions while striving to comply with federal, state and local regulatory guidelines.
About MangoRx
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including the outcome of certain outstanding legal matters, claims and allegations, the requirement that the Company spend cash and management’s resources on such matters, even if the Company ultimately prevails in such matters, risks associated with certain counterparties to lawsuits having significantly greater resources than us, settlements we may choose to enter into in the future and the terms thereof, and potential regulatory reviews, inquiries or lawsuits, which are brought about by claims made in private lawsuits; our ability to meet Nasdaq’s minimum bid price requirement and other continued listing requirements of Nasdaq, including the fact that the Company does not currently comply with Nasdaq’s minimum bid price requirement; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our products which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions and risks associated with related party relationships and agreements; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our products; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.
More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three and six months ended June 30, 2024, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow MangoRx on social media:
https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
FAQ
What claims has Eli Lilly made against MangoRx (MGRX)?
How has MangoRx (MGRX) responded to Eli Lilly's claims?
What is MangoRx's (MGRX) stance on providing its products?
Will the lawsuit affect MangoRx's (MGRX) operations?
